fda approved glp-1 receptor agonists Evolution of GLP‐1 for Diabetes Treatment GI Adverse Effects of Glucagon-Like

doi: 10.23876/j.krcp.21.014 45 SmigielKSSrivastavaSStolleyJMCampbellDJ

Youve likely heard about the incredible results of GLP-1 (glucagon-like peptide-1) medications, such as semaglutide, liraglutide, and tirzepatide, for weight loss in obese and overweight patients and type 2 diabetes mellitus

I go, Oh, my gosh, we're going

For research purposes, the practical use cases are: GLP-1 plateau rescue adding cagrilintide to a stalled semaglutide or tirzepatide protocol GLP-1 dose reduction using cagrilintide to maintain weight loss while tapering GLP-1 Standalone titration cagrilintide at 2.4 mg/week produced ~8-10% weight loss in monotherapy trials But here's the synthesis problem: cagrilintide has the same lipid-conjugation chemistry as semaglutide